Methods of screening a subject to determine whether or not they are at risk of having an adverse reaction to metal debris (ARMD), also known as adverse local tissue reaction (ALTR), methods of screening compounds for use in preventing or ameliorating such an adverse response and compounds for use in treating a subject.

The present disclosure relates to a kit for quantitative detection using a fluorescent microarray, and belongs to the technical field of protein detection. The kit of the present disclosure includes a detection plate and a detection antibody coupled with fluorescent microspheres, where the detection plate is provided with a plurality of reaction chambers; the reaction chamber is provided with an opening, and an inner bottom surface of the reaction chamber is provided with a plurality of detection sites that are arranged side by side along a length direction of the reaction chamber at an interval. The kit of the present disclosure may detect allergen-specific IgE, IgG and IgA with high sensitivity, as well as rapidly and quantitatively detect an allergen-specific antibody IgE, IgG and IgA concentration in human serum or plasma, and may screen dozens of allergens at a time.

The present invention relates to Lrig1 (leucine-rich and immunoglobulin-like domains 1) protein, a cell surface antigen specifically present on the surface of immune cells, and various uses thereof.

The invention relates to a method for binding or capturing autoantibodies directed to various Glycoprotein 2 (GP2) isoforms. In particular the invention provides an in vitro method for the diagnosis of an autoimmune disorder by the detection of autoantibodies that bind one or more isoforms of GP2. The invention is characterized by the provision of multiple isoforms of GP2 as autoantibody targets and encompasses the practical utilization of the finding that the isoform specificity of anti-GP2 autoantibodies enables determination of particular autoimmune diseases. The invention also provides a system and kit developed for carrying out the claimed method. The present invention is useful for determining whether a sample from an individual comprises autoantibodies associated with an autoimmune disease, and for differentiating between multiple autoimmune diseases that exhibit similar symptoms, such as Celiac disease (CeD), Crohn's disease (CD), primary sclerosing cholangitis (PSC), and/or ulcerative colitis (UC).

Provided are peptide biomarkers for diagnosis of allergy, monitoring development of clinical tolerance in an allergic individual, and predicting whether an allergic subject is likely to develop clinical or natural tolerance over time. The invention also relates to diagnostic methods and diagnostic kits employing the peptide biomarkers.

The present disclosure is directed towards modifying binding molecules in order to minimize pre-existing binding interactions, including binding molecules engineered to minimize or mitigate background reactivity in a sample matrix caused by drug non-specific binding interactions.

The present disclosure relates to antibodies and binding fragments to a Tenascin, in particular the FBG domain of a Tenascin, which are potentially less immunogenic than the parent antibody. The disclosure also relates to compositions comprising the antibody or binding fragment and use of any one of the same for diagnosis, prognosis and/or treatment of disorders such as those associated with chronic inflammation. The disclosure further provides methods of making the antibodies.

Methods of treating fibrotic diseases and disorders including Systemic sclerosis (SSc) are provided. Methods include, for example, administering to a subject an effective amount of an antagonist/inhibitor of PTP4A1 protein expression or activity to treat a fibrotic disease or disorder such as SSc, or an associated pathology such as organ or skin fibrosis.

A method for treating a gluten-induced disease, such as celiac disease, in a subject in need thereof is provided. The method comprises administering to the subject at least one agent that activates aryl hydrocarbon receptor such as AhR agonists, bacterial probiotics with AhR agonist activity, and IL-22 agonists, polypeptides and nucleic acid.

The invention includes compositions comprising a therapeutic agent that decreases the population of pathological CD4g13 T cells, g13Th1 or g13Th2, in a subject and compositions comprising a therapeutic agent that increases the population of protective CD4g13 T cells, g13Th1 or g13Th2, in a subject. The invention also includes methods for treating an inflammatory or autoimmune disease in a subject by administering to the subject an effective amount of a therapeutic agent that increases the population of protective CD4g13 T cells, methods for detecting a protective or pathological immune response and methods for stimulating a protective CD4g13 T cell-mediated immune response to a cell population or a local tissue or organ in a subject in need thereof. The invention further includes a kit for diagnosing a pathological or protective g13Th1 or g13Th2 T cell responses in a subject.